Sign in
4

Changes in Ownership

Krystal Biotech, Inc. Filed Acc 0001860010-23-000004

Chief Commercial Officer sold 12,500 shares at an average $128.61 ($1,607,635)

  • Chief Commercial Officer acquired 12,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

ORTH ANDREW C. · Chief Commercial Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2023-06-09 Exercise or conversion : show line 1 in the form 10b5-1 +12,500 $63.55 $794,375 12,600 D
2023-06-09 Sale : show line 2 in the form 10b5-1 −5,261 $128.10 $673,958 7,339 D
2023-06-09 Sale : show line 3 in the form 10b5-1 −6,906 $128.94 $890,488 433 D
2023-06-09 Sale : show line 4 in the form 10b5-1 −333 $129.70 $43,189 100 D
Open-market sales · 12,500 sh · avg $128.61 · $1,607,635

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-06-09 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) −12,500 37,500 D
Loading xslF345X04/wk-form4_1686351600.xml…